BGOG-ov86/RAINFOL-02

A phase 3 randomized, open-label study of Rinatabart Sesutecan (Rina-S) versus treatment of investigator’s choice (IC) in patients with platinum resistant ovarian cancer

Open
Trial drug
Rina-S
Grade
High grade
Prior lines
1, 2, 3, 4
Histology
Serous, Endometrioid
Platin
Platinum resistant
Secondary platinum refractory
Phase
II

Treatment

This study consists of two different treatment options:

  • Rinatabart Sesutecan (Rina-S)

  • Standard therapy (paclitaxel, PLD, gemictabine or topotecan)

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.